Sharekhan

BUY NOW Buy Beryl Drugs Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Beryl Drugs Ltd

Thu 2/04/2026,16:1:0

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

What’s Your Call?

Collective community sentiment on Beryl Drugs Ltd

Your Vote -

Buy

50.00%

Hold

0.00%

Sell

50.00%

50.00%

2 users have voted

No Records Found

Option Chain

Analyzes market sentiment, predicts Beryl Drugs Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Beryl Drugs - FIXES RECORD DATE FOR THE PURPOSE OF EXTRA ORDINARY GENERAL MEETING OF THE COMPANY

    1 Apr 2026, 5:20PM RECORD DATE

  • Beryl Drugs - INTIMATION OF E-VOTING DATES FOR THE PURPOSE OF EOGM OF THE COMPANY

    1 Apr 2026, 5:11PM INTIMATION OF E-VOTING DATES FOR THE PURPOSE OF EOGM OF THE COMPANY

  • Beryl Drugs - EGM ON 11TH MAY, 2026 AT 11:00 A.M

    1 Apr 2026, 4:57PM EGM ON 11TH MAY, 2026 AT 11:00 AM AT KANCHAN PALACE COMMUNITY HALL, NIPANIA RING ROAD, INDORE- 452001

  • Beryl Drugs - FIXES RECORD DATE FOR THE PURPOSE OF EXTRA ORDINARY GENERAL MEETING

    1 Apr 2026, 4:50PM FIXES RECORD DATE FOR THE PURPOSE OF EXTRA ORDINARY GENERAL MEETING

  • Beryl Drugs - Board Meeting Outcome for OUTCOME OF BOARD MEETING

    1 Apr 2026, 4:45PM OUTCOME OF BOARD MEETING

  • Beryl Drugs - DISCLOSURE UNDER REGULATION 7(2) OF SEBI (PROHIBITION OF INSIDER TRADING) REGULATIONS, 2015

    25 Mar 2026, 9:24PM DISCLOSURE UNDER REGULATION 7(2) OF SEBI(PROHIBITION OF INSIDER TRADING) REGULATIONS, 2015

  • Beryl Drugs - DISCLOSURE UNDER REGULATION 29(2) OF SEBI(SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS) REGULATIONS, 2011

    25 Mar 2026, 9:18PM DISCLOSURE UNDER REGULATION 29(2) OF SEBI(SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOEVRS)REGULATIONS, 2011

  • Beryl Drugs - DISCLOUSRE UNDER REGULATION 7(2) OF SEBI(PROHIBITION OF INSIDER TRADING )REGULATIONS, 2015

    24 Mar 2026, 4:44PM DISCLOSURE UNDER REGULATION 7(2) OF SEBI (PROHIBITION OF INSIDER TRADING) REGULATIONS, 2015

  • Beryl Drugs - DISCLOSURE UNDER REGULATION 29(2) UNDER SEBI (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVER) REGULATIONS, 2011

    24 Mar 2026, 4:40PM DISCLOSURE UNDER REGULATION 29(2) UNDER SEBI (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVER) REGULATIONS, 2011

  • Beryl Drugs - DISCLOSURE UNDER REGULATION 7(2) OF SEBI (PROHIBITION OF INSIDER TRADING) REGULATIONS, 2015

    21 Mar 2026, 5:28PM DISCLOSURE UNDER REGULATION 7(2) OF SEBI (PROHIBITION OF INSIDER TRADING) REGULATIONS, 2015

  • Beryl Drugs - DISCLOSURE UNDER REGULATION 29(2) OF SEBI (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS)REGULATIONS, 2011

    21 Mar 2026, 5:22PM DISCLOSURE UNDER REGULATION 29(2) OF SEBI (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS) REGULATIONS, 2011

  • Beryl Drugs - Board Meeting Intimation for Consider And Approve The Date And Notice Of Extra Ordinary General Meeting (EOGM)

    20 Mar 2026, 5:52PM Beryl Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/04/2026 ,inter alia, to consider and appr

  • Beryl Drugs - SUBMISSION OF DISCLOSURE UNDER REGULATION 7(2)

    17 Mar 2026, 1:08PM SUBMISSION OF DISCLOSURE UNDER REGULATION 7(2)

  • Beryl Drugs - SUBMISSION OF DISCLOSURE UNDER REGULATION 29(2)

    17 Mar 2026, 12:59PM SUBMISSION OF DISCLOSURE UNDER REGULATION 29(2)

  • Beryl Drugs - Regulations 7 (2) Of Securities And Exchange Board Of India (Prohibition Of Insider Trading) Regulations, 2015

    14 Mar 2026, 2:33PM DISCLOSURE RECEIVED UNDER REGULATION 7(2) OF SECURITIES EXCHANGE BOARD OF INDIA(PROHIBITION OF INSIDER TRADING) REGULATIONS, 2015

  • Beryl Drugs - Submission Of Disclosure Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations

    14 Mar 2026, 2:24PM DISCLOSURE UNDER REGULATION 29(2) OF SEBI (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS) REGULATIONS, 2011 RECEIVED FROM MR. SUDHIR SETHI, PROMOTER

  • Beryl Drugs - Submission Of Disclosure Under Regulations 7 (2) Of Securities And Exchange Board Of India (Prohibition Of Insi

    13 Mar 2026, 3:31PM DISCLOSURE UNDER REGULATION 7(2) OF SEBI (PROHIBITION OF INSIDER TRADING) REGULATIONS, 2015

  • Beryl Drugs - Submission Of Disclosure Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations

    13 Mar 2026, 3:28PM DISCLOSURE RECEIVED FROM MR. SUDHIR SETHI UNDER REGULATION 29(2) OF SEBI (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS) REGULATIONS, 2011

  • Beryl Drugs - Submission Of Disclosure Under Regulations 7 (2) Of Securities And Exchange Board Of India (Prohibition Of Insi

    12 Mar 2026, 4:38PM Disclosure under Regulation 7(2) of SEBI (Prohobition of Insider Trading) Regulations, 2015

  • Beryl Drugs - Submission Of Disclosure Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations

    12 Mar 2026, 4:35PM Disclosure recieved from the Mr. sudhir sethi, promoter of the company under regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers

  • Beryl Drugs - Submission Of Disclosure Under Regulations 7 (2) Of Securities And Exchange Board Of India (Prohibition Of Insi

    11 Mar 2026, 2:17PM DISCLOSURE UNDER REGULATION 7(2) OF PROHIBITION OF INSIDER TRADING

  • Beryl Drugs - Submission Of Disclosure Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations

    11 Mar 2026, 2:10PM disclosure received from Mr. sudhir sethi tthe main promoter of the company under regulation 29(2) of SEBI (SUBSTANTIAL ACQUISITION OF SHARES AND TAKE

  • Beryl Drugs posts Q3 net loss of Rs 0.17 cr

    9 Feb 2026, 5:40PM The company reported standalone net loss during the quarter stood at Rs 0.17 crore compared to net profit of Rs 0.05 crore in the previous year quarte

  • Beryl Drugs - UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2025

    9 Feb 2026, 4:43PM UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2025

  • Beryl Drugs - Board Meeting Outcome for OUTCOME OF BOARD MEETING

    9 Feb 2026, 4:38PM OUTCOME OF BOARD MEETING

  • Beryl Drugs - Board Meeting Intimation for To Consider And Approve The Unaudited Quarterly Financial Results For The Quarter

    31 Jan 2026, 7:55PM Beryl Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2026 ,inter alia, to consider and appr

  • Beryl Drugs Ltd. has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2025

    10 Jan 2026, 2:42PM As of December 2025, 26.38% is owned by Indian Promoters and 73.62% by Public. <p align=justify> Top four Promoters holding highest number of shares o

  • Beryl Drugs Ltd. - Compliance-57 (5) : intimation after the end of quarter

    6 Jan 2026, 11:23PM NON APPLICABILITY CERTIFICATE UNDER REGULATION 57(5) FOR THE QUARTER ENDED 31.12.2025

  • Beryl Drugs Ltd. - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    6 Jan 2026, 11:22PM COMPLIANCE CERTIFICATE UNDER REGULATION 74(5) FOR THE QUARTER ENDED 31ST DECEMBER, 2025

  • Beryl Drugs Ltd. - Announcement under Regulation 30 (LODR)-Change in Management

    5 Jan 2026, 7:24PM CONSIDERATION OF APPOINTMENT OF MRS. NEHA SARDA AS INDEPENDENT DIRECTOR OF THE COMPANY SUBJECT TO THE APPROVAL OF SHAREHOLDERS IN GENERAL MEETING

  • Beryl Drugs Ltd. - Announcement under Regulation 30 (LODR)-Change in Management

    5 Jan 2026, 7:22PM APPOINTMENT OF MR SHAILENDRA PATHAK AS AN ADDITIONAL DIRECTOR SUBJECT TO APPROVAL OF SHAREHOLDERS

  • Beryl Drugs Ltd. - Appointment of Company Secretary and Compliance Officer

    5 Jan 2026, 7:18PM APPOINTMENT OF MR. KAMLESH GUPTA AS COMPANY SECRETARY AND COMPLIANCE OFFICER OF THE COMPANY

  • Beryl Drugs Ltd. - Announcement under Regulation 30 (LODR)-Cessation

    5 Jan 2026, 7:15PM RESIGNATION OF MRS. NEHA SHARMA, COMPANY SECRETARY OF THE COMPANY W.E.F 3RD JANUARY, 2026
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Beryl Drugs Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 13.5773 14.0172 12.6085 12.5872 12.2693
Liabilities 13.5773 14.0172 12.6085 12.5872 12.2693
Equity 5.0937 5.0937 5.0937 5.0937 5.0936
Gross Profit 1.2324 2.2788 1.9451 0.408 1.4482
Net Profit 0.5788 0.7686 0.766 -0.659 0.2396
Cash From Operating Activities 2.6366 0.8203 2.4804 -0.2867 0.3777
NPM(%) 2.73 2.87 2.84 -4.51 1.7
Revenue 21.1462 26.7296 26.8878 14.6037 14.0929
Expenses 19.9138 24.4508 24.9427 14.1957 12.6446
ROE(%) 6.23 8.28 8.25 -7.1 2.58

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Beryl Drugs Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 658.30 7.18 38.87 10.88 301.39 0.76
Lotus Eye Hospital and Institute Ltd 103.65 2.02 330.68 39.64 3.55 0.00
Bharat Immunological and Biologicals Corporation Ltd 16.82 6.73 0.00 82.30 -39.50 0.00
Astec Lifesciences Ltd 540.10 -3.09 0.00 37.38 -604.75 0.00

Company Info

1994 -The company was incorporated as a medicine pharmaceutical manufacturer. 2007 -The board of directors of the company at its meeting held on Nov.16, 2007 decided to issue 1.50 million equity shares and 2 million warrants to promoters and other strategic investors on preferential basis. -Board of the company had increased the authorized share capital of the company from Rs 5.50 crores to Rs 10.00 crores. 2008 -Board of directors of the company had approved to issue 35 lacs warrants to promoters and other strategic investors on preferential basis. 2015 -Beryl Drugs, MPPHSCL sign deal worth Rs 11.8 crores.

1994 -The company was incorporated as a medicine pharmaceutical manufacturer. 2007 -The board of directors of the company at its meeting held on Nov.16, 2007 decided to issue 1.50 million equity shares and 2 million warrants to promoters and other strategic investors on preferential basis. -Board of the company had increased the authorized share capital of the company from Rs 5.50 crores to Rs 10.00 crores. 2008 -Board of directors of the company had approved to issue 35 lacs warrants to promoters and other strategic investors on preferential basis. 2015 -Beryl Drugs, MPPHSCL sign deal worth Rs 11.8 crores.

Read More

Parent Organisation

Beryl Drugs Ltd.

Founded

24/08/1993

Managing Director

Mr.Sanjay Sethi

NSE Symbol

FAQ

The current price of Beryl Drugs Ltd is

The 52-week high for Beryl Drugs Ltd is

The market capitalization of Beryl Drugs Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Beryl Drugs Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Beryl Drugs Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Beryl Drugs Ltd shares.

The CEO of Beryl Drugs Ltd is Mr.Sanjay Sethi, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT